Leinco Technologies, Inc.
excellence in early discovery research™

Anti-Human IL 12/23 (Briakinumab) [Clone ABT-874] — Fc Muted™

Biosimilar Recombinant Human Monoclonal Antibody

Product Information

Product No.:	LT505
Clone:	ABT-874
RRID:	AB_2893967
Isotype:	Human Human IgG1λ
Storage:	Sterile 2-8°C

Product Description

Specificity:
This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Briakinumab. Briakinumab recognizes both human IL12 and IL23 via IL-12/23p40. This product is for research use only.

Antigen Distribution:
IL-12 is produced by dendritic cells, macrophages, neutrophils, and human B-lymphoblastoid cells. IL-23 is mainly secreted by activated dendritic cells, macrophages or monocytes.

Background:
Briakinumab is a human monoclonal antibody targets the p40 subunit shared by interleukins 12 and 23. IL-12 associates with IL-23α to form the heterodimeric cytokine IL-23. IL-23 is associated with various autoimmune inflammatory diseases, and is particularly highly expressed in psoriasis skin lesions. In addition, IL-23 is suspected to play a role in tumorigenesis. Briakinumab binds to and neutralizes human IL-12 and IL-23 (via their shared p40 subunit) and is being investigated for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. Anti-Human IL 12/23 (Briakinumab) utilizes the same variable regions from the therapeutic antibody Briakinumab making it ideal for research projects.

Known Reactivity Species:
Human

Expression Host:
HEK-293 Cells

Format:
Purified No Carrier Protein

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

410 Axminister Dr, St. Louis, MO 63026 (800) 538-1145 leincoglobal@leinco.com

Immunogen:
This antibody was produced by phage display technology.

Formulation
This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Purity
≥95% by SDS Page, ≥95% monomer by analytical SEC

Endotoxin
< 1.0 EU/mg as determined by the LAL method

Storage and Stability
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. **Avoid Repeated Freeze Thaw Cycles.**

Product Preparation
Recombinant biosimilar antibodies are manufactured in an animal free facility using only *in vitro* protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Pathogen Testing
To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco's recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Applications
Applications and Recommended Usage (Quality Tested By Leinco):

FC The suggested concentration for Briakinumab biosimilar antibody for staining cells in flow cytometry is ≤ 0.25 µg per 10^6 cells in a volume of 100 µl. Titration of the reagent is recommended for optimal performance for each application.

Other Applications Reported in Literature:

B
FA
WB
IP
ELISA

410 Axminister Dr, St. Louis, MO 63026 (800) 538-1145 leincoglobal@leinco.com

N
IF

Country of Origin
USA

References
1. Vsn, M. *et al. (2016) VALUE IN HEALTH 19* ***PSS5****:A123*

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

410 Axminister Dr, St. Louis, MO 63026 (800) 538-1145 leincoglobal@leinco.com